oxybutynin has been researched along with Diabetes Mellitus in 9 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A microdevice that offers glucagon supplements in a safe, non-invasive, and glucose-responsive manner is ideal for avoiding fatal hypoglycemia consequences from insulin overdosage during daily diabetes treatment." | 4.12 | Shrinking Fabrication of a Glucose-Responsive Glucagon Microneedle Patch. ( Fu, R; Gu, Z; Han, X; Li, S; Wang, Z; Wen, D; Wu, Y, 2022) |
| " Here we present a novel intraepidermal delivery technology (delivered site at epidermis layer, <150 μm) by combining skin pretreatment with short microneedles (<150 μm in length) and iontophoresis transdermal patch (enhanced transport via electrical field) that can provide a continuous basal dose and on-demand bolus dosing for mealtime insulin needs." | 1.38 | Simultaneous basal-bolus delivery of fast-acting insulin and its significance in diabetes management. ( Gao, Y; Li, F; Qin, G; Qiu, Y; Wu, Y; Xu, B; Zhang, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Fu, R | 1 |
| Han, X | 1 |
| Wen, D | 1 |
| Wu, Y | 2 |
| Li, S | 1 |
| Gu, Z | 2 |
| Lemmerman, LR | 1 |
| Das, D | 1 |
| Higuita-Castro, N | 1 |
| Mirmira, RG | 1 |
| Gallego-Perez, D | 1 |
| Fonseca, DFS | 1 |
| Costa, PC | 1 |
| Almeida, IF | 1 |
| Dias-Pereira, P | 1 |
| Correia-Sá, I | 1 |
| Bastos, V | 1 |
| Oliveira, H | 1 |
| Duarte-Araújo, M | 1 |
| Morato, M | 1 |
| Vilela, C | 1 |
| Silvestre, AJD | 1 |
| Freire, CSR | 1 |
| Wynn, P | 1 |
| Jahn, LG | 1 |
| Capurro, JJ | 1 |
| Levy, BL | 1 |
| Berlin, I | 1 |
| Jacob, N | 1 |
| Coudert, M | 1 |
| Perriot, J | 1 |
| Schultz, L | 1 |
| Rodon, N | 1 |
| Qin, G | 1 |
| Gao, Y | 1 |
| Zhang, S | 1 |
| Qiu, Y | 1 |
| Li, F | 1 |
| Xu, B | 1 |
| Bohannon, N | 1 |
| Bergenstal, R | 1 |
| Cuddihy, R | 1 |
| Kruger, D | 1 |
| List, S | 1 |
| Massaro, E | 1 |
| Molitch, M | 1 |
| Raskin, P | 1 |
| Remtema, H | 1 |
| Strowig, S | 1 |
| Whitehouse, F | 1 |
| Brunelle, RL | 1 |
| Dreon, D | 1 |
| Tan, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does Dose Adjustment of Nicotine Replacement Therapies According to Saliva Cotinine Increase Efficacy of These Treatments of Assistance To the Nicotinic Weaning Of the High-Risk Patients?[NCT00235313] | Phase 4 | 300 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| The Effects of Finesse on Glycemic Control in Adults With Diabetes Using MDI: Finesse vs. Pen or Syringe and Vial as Bolus Prandial Insulin Device[NCT01073566] | Phase 2 | 38 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Standard deviation of 7 daily blood glucose values (3 pre-meal, 3 post-meal, and bedtime) for 3 days (NCT01073566)
Timeframe: 6 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Finesse | 3.18 |
| Usual Injection Device | 3.63 |
Subject satisfaction with insulin delivery was assessed by self-report on the validated Insulin Delivery System Rating Questionnaire. Scale is 0-100. Higher score is better. (NCT01073566)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Finesse | 82.9 |
| Usual Injection Device | 54.9 |
Equivalence of Finesse to Usual Injection Device in Mean Daily Blood Glucose (NCT01073566)
Timeframe: 6 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Finesse | 8.61 |
| Usual Injection Device | 9.02 |
Severe hypoglycemia is defined as episodes in which the patient experienced coma, seizure, or suspected seizure or impairment sufficient to require the assistance of another person and either the blood glucose level is measured and found to be <50 mg/dl or the clinical manifestations were reversed by oral carbohydrate, subcutaneous glucagon, or intravenous glucose. (NCT01073566)
Timeframe: 6 weeks
| Intervention | episodes (Number) |
|---|---|
| Finesse | 0 |
| Usual Injection Device | 0 |
1 review available for oxybutynin and Diabetes Mellitus
| Article | Year |
|---|---|
Nanomedicine-Based Strategies for Diabetes: Diagnostics, Monitoring, and Treatment.
Topics: Cell- and Tissue-Based Therapy; Diabetes Mellitus; Humans; Insulin; Monitoring, Physiologic; Nanogel | 2020 |
2 trials available for oxybutynin and Diabetes Mellitus
| Article | Year |
|---|---|
Adjustment of nicotine replacement therapies according to saliva cotinine concentration: the ADONIS* trial-a randomized study in smokers with medical comorbidities.
Topics: Administration, Buccal; Cardiovascular Diseases; Comorbidity; Cotinine; Counseling; Diabetes Mellitu | 2011 |
Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus; Glycated Hemoglobin; | 2011 |
6 other studies available for oxybutynin and Diabetes Mellitus
| Article | Year |
|---|---|
Shrinking Fabrication of a Glucose-Responsive Glucagon Microneedle Patch.
Topics: Animals; Biocompatible Materials; Diabetes Mellitus; Glucagon; Glucose; Hypoglycemia; Insulin; Mice; | 2022 |
Pullulan microneedle patches for the efficient transdermal administration of insulin envisioning diabetes treatment.
Topics: Administration, Cutaneous; Diabetes Mellitus; Drug Delivery Systems; Glucans; HaCaT Cells; Humans; H | 2020 |
NEW FOR YOU! These innovative products aim to help make diabetes self-management easier.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus; Drug Combinations; Glucose; Humans; | 2017 |
Innovation.
Topics: Biomedical Research; Blood Glucose Self-Monitoring; Diabetes Mellitus; Diffusion of Innovation; Hist | 2016 |
Comparative dose accuracy of durable and patch insulin infusion pumps.
Topics: Absorption; Diabetes Mellitus; Dose-Response Relationship, Drug; Durable Medical Equipment; Equipmen | 2013 |
Simultaneous basal-bolus delivery of fast-acting insulin and its significance in diabetes management.
Topics: Administration, Cutaneous; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Insu | 2012 |